[The clinical efficacy of the first Russian angiotensin-converting enzyme inhibitor methiopril in patients with heart failure].
Changes in central hemodynamics as recorded by tetrapolar rheography were investigated in 90 coronary heart disease (CHD) patients with circulatory insufficiency (CI) receiving methiopril. Relevant clinical response was registered in 94%, hemodynamic in 83% of patients. Those with CI stage IIA and IIB benefited more. Arterial pressure went down significantly only in CHD patients with arterial hypertension. Tachycardia patients showed a reduction in pulse rate absent in bradycardia. Cardiac output increased at the expense of low afterload. Efficient doses averaged 300 mg/day.
Glezer
M G
MG
Orlova
L L
LL
Titova
D Kh
DKh
Shvarts
G Ia
GIa
D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000188:drug therapy / Q000503:physiopathology; D013607:Tablets; D013997:Time Factors
D000806:Angiotensin-Converting Enzyme Inhibitors; D013607:Tablets
Klinicheskaia éffektivnost' pervogo otechestvennogo ingibitora angiotenzinprevrashchaiushchego fermenta metioprila u bol'nykh s serdechnoĭ nedostatochnost'iu.